GSA Capital Partners LLP Buys 106,167 Shares of 10x Genomics $TXG

GSA Capital Partners LLP raised its stake in 10x Genomics (NASDAQ:TXG) by 708.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 121,144 shares of the company’s stock after acquiring an additional 106,167 shares during the period. GSA Capital Partners LLP owned approximately 0.10% of 10x Genomics worth $1,416,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Allworth Financial LP increased its stake in 10x Genomics by 150.4% during the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock valued at $26,000 after purchasing an additional 1,364 shares in the last quarter. True Wealth Design LLC grew its holdings in shares of 10x Genomics by 1,552.5% during the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock valued at $42,000 after buying an additional 3,369 shares during the last quarter. Abich Financial Wealth Management LLC purchased a new stake in shares of 10x Genomics during the third quarter valued at approximately $56,000. EverSource Wealth Advisors LLC increased its position in shares of 10x Genomics by 203.9% during the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after acquiring an additional 5,025 shares in the last quarter. Finally, Focus Partners Wealth purchased a new position in 10x Genomics in the 1st quarter worth approximately $92,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Up 2.8%

Shares of NASDAQ:TXG opened at $18.62 on Wednesday. The stock has a market capitalization of $2.36 billion, a PE ratio of -53.20 and a beta of 2.24. The firm’s 50 day moving average price is $18.70 and its 200-day moving average price is $15.69. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $23.56.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. 10x Genomics had a negative net margin of 6.77% and a negative return on equity of 6.99%. The business had revenue of $166.03 million during the quarter, compared to analysts’ expectations of $160.35 million. During the same period in the prior year, the company earned ($0.40) earnings per share. The firm’s revenue was up .6% on a year-over-year basis. Analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 8,283 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $157,377.00. Following the completion of the transaction, the insider directly owned 432,605 shares in the company, valued at approximately $8,219,495. The trade was a 1.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Adam Taich sold 11,888 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $225,872.00. Following the sale, the chief financial officer owned 297,385 shares in the company, valued at approximately $5,650,315. The trade was a 3.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 33,432 shares of company stock worth $635,208. Corporate insiders own 10.03% of the company’s stock.

Analyst Upgrades and Downgrades

TXG has been the subject of a number of research analyst reports. Bank of America set a $21.00 target price on 10x Genomics in a report on Monday, January 12th. Stifel Nicolaus lifted their price objective on 10x Genomics from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a research note on Monday, December 22nd. Zacks Research lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Finally, Piper Sandler boosted their price objective on shares of 10x Genomics from $15.00 to $19.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $17.68.

10x Genomics Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.